Global Blood Therapeutics Inc (GBT) Insider Peter Radovich Sells 15,000 Shares

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Peter Radovich sold 15,000 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider now directly owns 17,684 shares of the company’s stock, valued at $884,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Peter Radovich also recently made the following trade(s):

  • On Thursday, February 1st, Peter Radovich sold 812 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $57.30, for a total transaction of $46,527.60.
  • On Tuesday, January 23rd, Peter Radovich sold 30,000 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $60.00, for a total transaction of $1,800,000.00.
  • On Monday, October 30th, Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $35.00, for a total transaction of $437,500.00.

Global Blood Therapeutics Inc (GBT) traded up $1.20 during mid-day trading on Friday, reaching $60.80. 872,743 shares of the company traded hands, compared to its average volume of 1,170,000. The stock has a market cap of $2,850.00 and a P/E ratio of -23.84. Global Blood Therapeutics Inc has a 52 week low of $15.75 and a 52 week high of $64.50.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter last year, the firm earned ($0.58) EPS. analysts expect that Global Blood Therapeutics Inc will post -2.53 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Emory University purchased a new position in Global Blood Therapeutics during the 2nd quarter valued at about $1,442,000. Citigroup Inc. grew its position in shares of Global Blood Therapeutics by 1,544.9% in the 2nd quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock worth $2,402,000 after buying an additional 82,480 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Global Blood Therapeutics by 211.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock worth $8,686,000 after buying an additional 215,690 shares during the last quarter. Family Management Corp purchased a new position in shares of Global Blood Therapeutics in the 3rd quarter worth approximately $351,000. Finally, Perceptive Advisors LLC grew its position in shares of Global Blood Therapeutics by 8.4% in the 3rd quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after buying an additional 330,139 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

GBT has been the subject of several research reports. Morgan Stanley reiterated an “overweight” rating and set a $56.00 price objective (up previously from $51.00) on shares of Global Blood Therapeutics in a research report on Friday, October 6th. BidaskClub upgraded shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC set a $51.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 18th. Zacks Investment Research lowered shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Finally, HC Wainwright set a $73.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday, December 11th. Two investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $63.27.

COPYRIGHT VIOLATION NOTICE: “Global Blood Therapeutics Inc (GBT) Insider Peter Radovich Sells 15,000 Shares” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/03/global-blood-therapeutics-inc-gbt-insider-peter-radovich-sells-15000-shares-of-stock.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply